Minerva Lozano | UAEH - Academia.edu (original) (raw)

Papers by Minerva Lozano

Research paper thumbnail of Efectos adversos y paliativos de los canabinoides

Research paper thumbnail of Achieving competitiveness through setup time reduction

2015 International Conference on Industrial Engineering and Operations Management (IEOM), 2015

Research paper thumbnail of Differential progesterone effects on defensive burying and forced swimming tests depending upon a gradual decrease or an abrupt suppression schedules

Pharmacology Biochemistry and Behavior, 2006

A single dose of progesterone reduces the cumulative time in the defensive burying test and the i... more A single dose of progesterone reduces the cumulative time in the defensive burying test and the immobility in the forced swim test, whereas the abrupt suppression of repeated doses increases the anxiety indicators. Whether anxiety and despair indicators reduce by a gradually decreased schedule of progesterone is unknown. Therefore, we subjected adult ovariectomized Wistar rats to open field, defensive burying and forced swim tests. One group received a constant schedule of progesterone (0.50 mg, daily), abruptly suppressed (AS) after five days. Another group received a gradual reduction schedule of progesterone (GR: 0.84, 0.67, 0.50, 0.33, 0.17 mg, each day). Control group received vehicle (VEH). The GR group displayed similar crossing in the open field test as the VEH group (F(2,19) = 8.78, p < 0.002), but also the shortest cumulative time in defensive burying (F(2,28) = 13.3, p < 0.0001) and the shortest time in freezing (F(2,24) = 6.39, p < 0.006). In the forced swim test, the GR group displayed the shortest immobility time (F(2,19) = 12.1, p < 0.0005), the lowest number of immobility periods (F(2,19) = 4.26, p < 0.03) and the longest latency to the first period of immobility (F(2,1) = 4.06, p < 0.03). It is concluded that a gradually reduced schedule of progesterone reduces anxiety and despair in the Wistar rat.

Research paper thumbnail of Efectos del bupropión sobre depresión, ansiedad y abstinencia a nicotina

Artículo de revisión RESUMEN Los trastornos de ansiedad y depresión tienen alta prevalencia a niv... more Artículo de revisión RESUMEN Los trastornos de ansiedad y depresión tienen alta prevalencia a nivel mundial y notablemente ocurre comorbilidad entre trastornos afectivos y de ansiedad con el consumo de tabaco; en efecto, quienes padecen alteraciones del estado de ánimo son más propensos al tabaquismo. El bupropión es una aminocetona monocíclica (cloropropiofenona) químicamente relacionada con las feniletilaminas, con eficacia demostrada en modelos animales y clínicos como antidepresivo y ansiolítico y, produce menos efectos adversos que otros antidepresivos atípicos e inhibidores selectivos de la recaptura de serotonina. Además, el bupropión es un buen auxiliar en el manejo de la adicción a la nicotina y aunque se requieren más estudios, recién, se ha señalado su posible uso en el tratamiento del déficit de atención. En sus acciones antidepresivas, ansiolíticas y anti-tabaco parece participar la inhibición de la recaptura de dopamina y noradrenalina en neuronas corticales y algunas ...

Research paper thumbnail of Trazodona, un antidepresivo atípico con propiedades ansiolíticas y sedantes

Research paper thumbnail of A Five-Day Gradual Reduction Regimen of Chlormadinone Reduces Premenstrual Anxiety and Depression: A Pilot Study

Archives of Medical Research, 2006

Background. Anxiety and depression commonly occur in premenstrual dysphoric disorder (PMDD). The ... more Background. Anxiety and depression commonly occur in premenstrual dysphoric disorder (PMDD). The PMDD symptomatology disappears once the menstrual cycle reinitiates, resembling a withdrawal syndrome. Methods. The present study is a pilot, controlled, double-blind study exploring the effectiveness of a premenstrual 5-day gradual reduction regimen of chlormadinone acetate on PMDD. Volunteers received an initial dose of 10 mg (five 2-mg tablets) on the 24 th day of the menstrual cycle and one-fifth of the dose less (one tablet) each day until a dose of 2 mg (one 2-mg tablet) was reached on the 28 th day of the menstrual cycle. The control group received placebo with a similar regimen. Results. The 5-day gradual reduction regimen of chlormadinone significantly improved (F 3.76 5 3.29, p !0.02) the daily symptoms report (DSR) scores by the third month of treatment. The resulting relative risk was 4.09 (confidence interval: 1.15-14.57, p !0.005, 95% CI). Compared to placebo, chlormadinone clinically and statistically reduced the severity of depression, anxiety, food cravings, mood swings and cramps. A statistical reduction of symptoms such as poor coordination, irritability, feeling out of control, hopelessness, decreased interest and headache was detected but was not clinically relevant. No changes occurred in concentration difficulties, tiredness, insomnia, swelling, breast tenderness and aches. As side effects, 30% of the volunteers showed changes in the length of the menstrual cycle, and 15% experienced dyspepsia. Conclusions. A 5-day gradual reduction regimen of chlormadinone improves some of the discomforting ailments associated with PMDD, namely, depression and anxiety. Ó 2006 IMSS. Published by Elsevier Inc.

Research paper thumbnail of Efectos adversos y paliativos de los canabinoides

Research paper thumbnail of Achieving competitiveness through setup time reduction

2015 International Conference on Industrial Engineering and Operations Management (IEOM), 2015

Research paper thumbnail of Differential progesterone effects on defensive burying and forced swimming tests depending upon a gradual decrease or an abrupt suppression schedules

Pharmacology Biochemistry and Behavior, 2006

A single dose of progesterone reduces the cumulative time in the defensive burying test and the i... more A single dose of progesterone reduces the cumulative time in the defensive burying test and the immobility in the forced swim test, whereas the abrupt suppression of repeated doses increases the anxiety indicators. Whether anxiety and despair indicators reduce by a gradually decreased schedule of progesterone is unknown. Therefore, we subjected adult ovariectomized Wistar rats to open field, defensive burying and forced swim tests. One group received a constant schedule of progesterone (0.50 mg, daily), abruptly suppressed (AS) after five days. Another group received a gradual reduction schedule of progesterone (GR: 0.84, 0.67, 0.50, 0.33, 0.17 mg, each day). Control group received vehicle (VEH). The GR group displayed similar crossing in the open field test as the VEH group (F(2,19) = 8.78, p < 0.002), but also the shortest cumulative time in defensive burying (F(2,28) = 13.3, p < 0.0001) and the shortest time in freezing (F(2,24) = 6.39, p < 0.006). In the forced swim test, the GR group displayed the shortest immobility time (F(2,19) = 12.1, p < 0.0005), the lowest number of immobility periods (F(2,19) = 4.26, p < 0.03) and the longest latency to the first period of immobility (F(2,1) = 4.06, p < 0.03). It is concluded that a gradually reduced schedule of progesterone reduces anxiety and despair in the Wistar rat.

Research paper thumbnail of Efectos del bupropión sobre depresión, ansiedad y abstinencia a nicotina

Artículo de revisión RESUMEN Los trastornos de ansiedad y depresión tienen alta prevalencia a niv... more Artículo de revisión RESUMEN Los trastornos de ansiedad y depresión tienen alta prevalencia a nivel mundial y notablemente ocurre comorbilidad entre trastornos afectivos y de ansiedad con el consumo de tabaco; en efecto, quienes padecen alteraciones del estado de ánimo son más propensos al tabaquismo. El bupropión es una aminocetona monocíclica (cloropropiofenona) químicamente relacionada con las feniletilaminas, con eficacia demostrada en modelos animales y clínicos como antidepresivo y ansiolítico y, produce menos efectos adversos que otros antidepresivos atípicos e inhibidores selectivos de la recaptura de serotonina. Además, el bupropión es un buen auxiliar en el manejo de la adicción a la nicotina y aunque se requieren más estudios, recién, se ha señalado su posible uso en el tratamiento del déficit de atención. En sus acciones antidepresivas, ansiolíticas y anti-tabaco parece participar la inhibición de la recaptura de dopamina y noradrenalina en neuronas corticales y algunas ...

Research paper thumbnail of Trazodona, un antidepresivo atípico con propiedades ansiolíticas y sedantes

Research paper thumbnail of A Five-Day Gradual Reduction Regimen of Chlormadinone Reduces Premenstrual Anxiety and Depression: A Pilot Study

Archives of Medical Research, 2006

Background. Anxiety and depression commonly occur in premenstrual dysphoric disorder (PMDD). The ... more Background. Anxiety and depression commonly occur in premenstrual dysphoric disorder (PMDD). The PMDD symptomatology disappears once the menstrual cycle reinitiates, resembling a withdrawal syndrome. Methods. The present study is a pilot, controlled, double-blind study exploring the effectiveness of a premenstrual 5-day gradual reduction regimen of chlormadinone acetate on PMDD. Volunteers received an initial dose of 10 mg (five 2-mg tablets) on the 24 th day of the menstrual cycle and one-fifth of the dose less (one tablet) each day until a dose of 2 mg (one 2-mg tablet) was reached on the 28 th day of the menstrual cycle. The control group received placebo with a similar regimen. Results. The 5-day gradual reduction regimen of chlormadinone significantly improved (F 3.76 5 3.29, p !0.02) the daily symptoms report (DSR) scores by the third month of treatment. The resulting relative risk was 4.09 (confidence interval: 1.15-14.57, p !0.005, 95% CI). Compared to placebo, chlormadinone clinically and statistically reduced the severity of depression, anxiety, food cravings, mood swings and cramps. A statistical reduction of symptoms such as poor coordination, irritability, feeling out of control, hopelessness, decreased interest and headache was detected but was not clinically relevant. No changes occurred in concentration difficulties, tiredness, insomnia, swelling, breast tenderness and aches. As side effects, 30% of the volunteers showed changes in the length of the menstrual cycle, and 15% experienced dyspepsia. Conclusions. A 5-day gradual reduction regimen of chlormadinone improves some of the discomforting ailments associated with PMDD, namely, depression and anxiety. Ó 2006 IMSS. Published by Elsevier Inc.